Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer (LBA 6)

Authors:
  • UMUrsula Matulonis
    Ursula Matulonis
  • JHJørn Herrstedt
    Jørn Herrstedt
  • AOAmit Oza
    Amit Oza
  • SMSven Mahner
    Sven Mahner
  • ARAndres Redondo
    Andres Redondo
  • DBDominique Berton
    Dominique Berton
  • JBJonathan Berek
    Jonathan Berek
  • CHCharlotte Haslund
    Charlotte Haslund
  • FMFrederik Marmé
    Frederik Marmé
  • AGAntonio González-Martín
    Antonio González-Martín
  • SBStéphanie Becourt
    Stéphanie Becourt
  • ATAnna Tinker
    Anna Tinker
Publisher website
Google Scholar
Abstract
No abstract available